ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
293 | (±¹¿Ü)SCI | The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma |
292 | (±¹¿Ü)SCIE | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
291 | (±¹¿Ü)SCIE | Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis |
290 | (±¹¿Ü)SCIE | Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab |
289 | (±¹¿Ü)SCIE | A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naive or opioid-resistant patients |
288 | (±¹¿Ü)SCIE | Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. |
287 | (±¹¿Ü)SCIE | A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naive or opioid-resistant patients |
286 | (±¹¿Ü)SCIE | "Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase" |
285 | (±¹¿Ü)SCIE | Efficacy and Safety of Atezolizumab plus Bevacizumab in Korean Patients with Advanced Hepatocellular Carcinoma |
284 | (±¹¿Ü)SCIE | Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. |
Copyright ¨Ï chamc, All rights reserved.